myeloma

September 29, 2022

New Clinician Spotlight: Muhamed Baljević

Specializing in myeloma, amyloidosis and other plasma cell disorders, hematologist and medical oncologist Muhamed Baljević, MD, recently joined Vanderbilt University Medical Center.

By VUMC News and Communications

April 30, 2014

Potential mechanism for myeloma drug’s variable toxicity

A genetic variant is associated with toxicity of the chemotherapy drug melphalan, and could guide individualized dosing for the medication.